Pharsight

Scenesse patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10076555 CLIVUNEL INC Methods of inducing melanogenesis in a subject
Feb, 2025

(7 months from now)

US8334265 CLIVUNEL INC Method of treatment of photodermatoses
Mar, 2029

(4 years from now)

Scenesse is owned by Clivunel Inc.

Scenesse contains Afamelanotide.

Scenesse has a total of 2 drug patents out of which 0 drug patents have expired.

Scenesse was authorised for market use on 08 October, 2019.

Scenesse is available in implant;subcutaneous dosage forms.

Scenesse can be used as increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (epp).

Drug patent challenges can be filed against Scenesse from 09 October, 2023.

The generics of Scenesse are possible to be released after 11 March, 2029.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-270) Oct 08, 2026
New Chemical Entity Exclusivity(NCE) Oct 08, 2024

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using AFAMELANOTIDE ingredient

NCE-1 date: 09 October, 2023

Market Authorisation Date: 08 October, 2019

Treatment: Increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (epp)

Dosage: IMPLANT;SUBCUTANEOUS

More Information on Dosage

SCENESSE family patents

Family Patents